Asia-Pacific Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026

Asia-Pacific Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026

Asia-Pacific scleroderma therapeutics market is expected to grow at a CAGR of 4.4% in the forecast period of 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.
Market Segmentation
By Type (Localized Scleroderma, Systemic Scleroderma), Treatment Type (Drug Treatment, Surgical Treatment, Therapy), End User (Hospital, Specialty Clinics, Homecare Settings, Others), Country (Japan, China, Australia, South Korea, India, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2026

Major growing sectors under the market segmentation are as follows:

• In type, systemic scleroderma segment is dominating due to its awareness and treatment availability for its associated diseases. There are many products for this segment on which the clinical trials are going on.

• In treatment type, the drug treatment is growing segment as there are various drugs available in the market for the treatment of scleroderma related complications.

• In end user, hospital has a larger market than other end users because the treatment takes place majorly in hospitals.

Key Market Players

The key market players for Asia-Pacific scleroderma therapeutics market are listed below:

• Argentis Pharmaceuticals, LLC.
• F. Hoffmann-La Roche Ltd
• AbbVie Inc.
• Pfizer Inc.
• Sanofi
• ALLERGAN
• viDA Therapeutics Inc.
• Novartis AG
• Active Biotech AB.
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Johnson & Johnson Services, Inc.
• AstraZeneca
• Daval International Limited
• Others

The single user license is non-downloadable and non-printable. Global Site license allows these actions.


1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of Asia-pacific Scleroderma Therapeutics Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Asia-pacific Scleroderma Therapeutics Market : Geographical Scope
2.3 Years Considered For The Study
2.4 Currency And Pricing
2.5 Dbmr Tripod Data Validation Model
2.6 Primary Interviews With Key Opinion Leaders
2.7 Dbmr Market Position Grid
2.8 Time Line
2.9 Multivariate Modelling
2.10 Secondary Sources
2.11 Assumptions
3 Market Overview
3.1 Drivers
3.1.1 Rising Cases Of Scleroderma
3.1.2 Increasing Access To Medical Insurance In The U.S.
3.1.3 Increasing Merger And Acquisitions
3.2 Restraints
3.2.1 Lack Of Curative Treatment
3.2.2 Stringent Regulations
3.2.3 Counterfeit Products
3.3 Opportunity
3.3.1 Unmet Patient Needs In Systemic Sclerosis
3.4 Challenge
3.4.1 Side Effects Of Drugs
4 Executive Summary
5 Premium Insights
6 Pipeline Products
7 Epidemiology
7.1 History Of Scleroderma:
7.2 Recent Incidence And Prevalence:
7.3 Cause Of Scleroderma:
7.4 Symptoms Of Scleroderma:
7.5 Managing Scleroderma:
8 Asia-pacific Scleroderma Therapeutics Market, By Type
8.1 Overview
8.2 Systemic Scleroderma
8.2.1 Limited Cutaneous Systemic Sclerosis Or Crest Syndrome
8.2.2 Diffuse Systemic Sclerosis
8.3 Localized Scleroderma
8.3.1 Morphea
8.3.2 Linear Scleroderma
9 Asia-pacific Scleroderma Therapeutics Market, By Treatment Type
9.1 Overview
9.2 Drug Treatment
9.2.1 Drug Treatment, By Type
9.2.1.1 Anti-inflammatory Drugs
9.2.1.2 Immunosuppressants
9.2.1.3 Corticosteroids
9.2.1.4 Proton Pump Inhibitors
9.2.1.5 Calcium Channel Blockers
9.2.1.6 Ace Inhibitors
9.2.1.7 H2 Blockers
9.2.1.8 Pde5 Inhibitors
9.2.1.9 Prostacyclin Analogues
9.2.1.10 Endothelin Receptor Antagonists
9.2.1.11 Chelating Agents (Edathamil Disodium)
9.2.1.12 Others
9.2.2 Drug Treatment, By Distribution Channel
9.2.2.1 Hospital Pharmacy
9.2.2.2 Retail Pharmacy
9.2.2.3 Online Pharmacy
9.2.2.4 Others
9.3 Surgical Treatment
9.4 Therapy
9.4.1 Ultraviolet Light Therapy
9.4.2 Physical Therapy
9.4.3 Others
10 Asia-pacific Scleroderma Therapeutics Market, By End User
10.1 Overview
10.2 Hospital
10.3 Specialty Clinics
10.4 Homecare Settings
10.5 Others
11 Asia-pacific Scleroderma Therapeutics Market, By Geography
11.1 Asia-pacific
11.1.1 Japan
11.1.2 China
11.1.3 Australia
11.1.4 South Korea
11.1.5 India
11.1.6 Singapore
11.1.7 Malaysia
11.1.8 Indonesia
11.1.9 Thailand
11.1.10 Philippines
11.1.11 Rest Of Asia-pacific
12 Asia-pacific Scleroderma Therapeutics Market, Company Landscape
12.1 Company Share Analysis: Asia-pacific
13 Company Profiles
13.1 Astrazeneca
13.1.1 Company Snapshot
13.1.2 Revenue Analysis
13.1.3 Geographical Presence
13.1.4 Product Portfolio (Pipeline)
13.1.5 Recent Developments
13.2 F. Hoffmann-la Roche Ltd
13.2.1 Company Snapshot
13.2.2 Reveneue Analysis
13.2.3 Geographical Presence
13.2.4 Product Portfolio
13.2.5 Recent Developments
13.3 Novartis Ag
13.3.1 Company Snapshot
13.3.2 Reveneue Analysis
13.3.3 Geographical Presence
13.3.4 Product Portfolio
13.3.5 Recent Developments
13.4 Pfizer Inc.
13.4.1 Company Snapshot
13.4.2 Reveneue Analysis
13.4.3 Geographical Presence
13.4.4 Product Portfolio
13.4.5 Recent Developments
13.5 Abbvie Inc.
13.5.1 Company Snapshot
13.5.2 Reveneue Analysis
13.5.3 Geographical Presence
13.5.4 Product Portfolio
13.5.5 Recent Developments
13.6 Active Biotech Ab.
13.6.1 Company Overview
13.6.2 Revenue Analysis
13.6.3 Product Portfolio
13.6.4 Recent Development
13.7 Allergan
13.7.1 Company Snapshot
13.7.2 Reveneue Analysis
13.7.3 Geographical Presence
13.7.4 Product Portfolio
13.7.5 Recent Developments
13.8 Argentis Pharmaceuticals, Llc.
13.8.1 Company Overview
13.8.2 Product Portfolio
13.8.3 Recent Developments
13.9 Bristol-myers Squibb Company
13.9.1 Company Overview
13.9.2 Revenue Analysis
13.9.3 Geographical Presence
13.9.4 Products Portfolio
13.9.5 Recent Developments
13.10 Daval International Limited
13.10.1 Company Snapshot
13.10.2 Geographical Presence
13.10.3 Product Portfolio
13.10.4 Recent Development
13.11 Glaxosmithkline Plc.
13.11.1 Company Overview
13.11.2 Revenue Analysis
13.11.3 Geographical Presence
13.11.4 Products Portfolio (Pipeline Development)
13.11.5 Recent Development
13.12 Johnson & Johnson Services, Inc.
13.12.1 Company Overview
13.12.2 Revenue Analysis
13.12.3 Geographical Presence
13.12.4 Product Portfolio (Pipeline)
13.12.5 Recent Developments
13.13 Sanofi
13.13.1 Company Snapshot
13.13.2 Reveneue Analysis
13.13.3 Geographical Presence
13.13.4 Product Portfolio
13.13.5 Recent Development
13.14 Vida Therapeutics Inc.
13.14.1 Company Overview
13.14.2 Product Portfolio
13.14.3 Recent Developments
14 Questionnaire
15 Related Reports
List Of Tables
Table 1 Insights About Clinical Trial Phases Of Various Drugs
Table 2 Incidence And Prevalence In Past Decade (Region)
Table 3 Asia-pacific Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 4 Asia-pacific Systemic Scleroderma In Scleroderma Therapeutics Market, By Region 2017-2026 (Usd Million)
Table 5 Asia-pacific Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 6 Asia-pacific Localized Scleroderma In Scleroderma Therapeutics Market, By Region 2017-2026 (Usd Million)
Table 7 Asia-pacific Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 8 Asia-pacific Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 9 Asia-pacific Drug Treatment In Scleroderma Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 10 Asia-pacific Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 11 Asia-pacific Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 12 Asia-pacific Surgical Treatment In Scleroderma Therapeutics Market, By Region 2017-2026 (Usd Million)
Table 13 Asia-pacific Therapy In Scleroderma Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 14 Asia-pacific Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 15 Asia-pacific Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 16 Asia-pacific Hospital In Scleroderma Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 17 Asia-pacific Specialty Clinics In Scleroderma Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 18 Asia-pacific Homecare Settings In Scleroderma Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 19 Asia-pacific Others In Scleroderma Therapeutics Market, By Region, 2017-2026 (Usd Million)
Table 20 Asia-pacific Scleroderma Therapeutics Market, By Country, 2017-2026 (Usd Million)
Table 21 Asia-pacific Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 22 Asia-pacific Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 23 Asia-pacific Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 24 Asia-pacific Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 25 Asia-pacific Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 26 Asia-pacific Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 27 Asia-pacific Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 28 Asia-pacific Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 29 Japan Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 30 Japan Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 31 Japan Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 32 Japan Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 33 Japan Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 34 Japan Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 35 Japan Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 36 Japan Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 37 China Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 38 China Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 39 China Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 40 China Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 41 China Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 42 China Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 43 China Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 44 China Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 45 Australia Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 46 Australia Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 47 Australia Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 48 Australia Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 49 Australia Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 50 Australia Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 51 Australia Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 52 Australia Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 53 South Korea Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 54 South Korea Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 55 South Korea Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 56 South Korea Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 57 South Korea Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 58 South Korea Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 59 South Korea Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 60 South Korea Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 61 India Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 62 India Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 63 India Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 64 India Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 65 India Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 66 India Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 67 India Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 68 India Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 69 Singapore Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 70 Singapore Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 71 Singapore Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 72 Singapore Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 73 Singapore Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 74 Singapore Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 75 Singapore Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 76 Singapore Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 77 Malaysia Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 78 Malaysia Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 79 Malaysia Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 80 Malaysia Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 81 Malaysia Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 82 Malaysia Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 83 Malaysia Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 84 Malaysia Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 85 Indonesia Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 86 Indonesia Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 87 Indonesia Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 88 Indonesia Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 89 Indonesia Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 90 Indonesia Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 91 Indonesia Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 92 Indonesia Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 93 Thailand Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 94 Thailand Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 95 Thailand Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 96 Thailand Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 97 Thailand Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 98 Thailand Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 99 Thailand Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 100 Thailand Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 101 Philippines Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 102 Philippines Localized Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 103 Philippines Systemic Scleroderma In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 104 Philippines Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 105 Philippines Drug Treatment In Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
Table 106 Philippines Drug Treatment In Scleroderma Therapeutics Market, By Distribution Channel, 2017-2026 (Usd Million)
Table 107 Philippines Therapy In Scleroderma Therapeutics Market, By Treatment Type, 2017-2026 (Usd Million)
Table 108 Philippines Scleroderma Therapeutics Market, By End User, 2017-2026 (Usd Million)
Table 109 Rest Of Asia-pacific Scleroderma Therapeutics Market, By Type, 2017-2026 (Usd Million)
List Of Figures
Figure 1 Below Is The Scleroderma Map Defining The Types
Figure 2 Asia-pacific Scleroderma Therapeutics Market: Segmentation
Figure 3 Asia-pacific Scleroderma Therapeutics Market: Data Triangulation
Figure 4 Asia-pacific Scleroderma Therapeutics Market: Droc Analysis
Figure 5 Asia-pacific Scleroderma Therapeutics Market: Asia-pacific Vs Regional Market Analysis
Figure 6 Asia-pacific Scleroderma Therapeutics Market: Company Research Analysis
Figure 7 Asia-pacific Scleroderma Therapeutics Market: Interview Demographics
Figure 8 Asia-pacific Scleroderma Therapeutics Market: Dbmr Market Position Grid
Figure 9 Drivers, Restraints, Opportunities And Challenges Of Asia-pacific Scleroderma Therapeutics Market
Figure 10 Asia-pacific Scleroderma Therapeutics Market: Segmentation
Figure 11 Rising Cases Of Scleroderma, Increasing Access To Medical Insurance In The U.S., Increasing Merger And Acquisitions Is Expected To Drive The Asia-pacific Scleroderma Therapeutics Market In The Forecast Period 2019 To
Figure 12 Systemic Scleroderma Is Expected To Account For The Largest Share Of The Asia-pacific Scleroderma Therapeutics Market In 2019 &
Figure 13 Asia-pacific Scleroderma Therapeutics Market: By Type ,
Figure 14 Asia-pacific Scleroderma Therapeutics Market: By Treatment Type ,
Figure 15 Asia-pacific Scleroderma Therapeutics Market: By End User,
Figure 16 Asia-pacific Scleroderma Therapeutics Market: Snapshot (2018)
Figure 17 Asia-pacific Scleroderma Therapeutics Market: By Country (2018)
Figure 18 Asia-pacific Scleroderma Therapeutics Market: By Country (2019 & 2026)
Figure 19 Asia-pacific Scleroderma Therapeutics Market: By Country (2018 & 2026)
Figure 20 Asia-pacific Scleroderma Therapeutics Market: By Type (2019-2026)
Figure 21 Asia-pacific Scleroderma Therapeutics Market: Company Share 2018 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook